Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Importance National guidelines endorse treatment with neoadjuvant therapy for borderline
resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains …

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in
the Western world with limited therapeutic options and dismal long-term survival. The …

PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for
resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

Importance Patients with locally advanced pancreatic cancer have historically poor
outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate …

Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …